369,741 Celldex Therapeutics, Inc. $CLDX Shares Sold by Pictet Asset Management Holding SA

Pictet Asset Management Holding SA cut its position in Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 40.3% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 547,667 shares of the biopharmaceutical company’s stock after selling 369,741 shares during the quarter. Pictet Asset Management Holding SA owned 0.70% of Celldex Therapeutics worth $17,750,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Abel Hall LLC grew its holdings in Celldex Therapeutics by 6.8% during the 3rd quarter. Abel Hall LLC now owns 6,237 shares of the biopharmaceutical company’s stock worth $202,000 after acquiring an additional 399 shares during the last quarter. AlphaCentric Advisors LLC grew its position in shares of Celldex Therapeutics by 4.0% in the 3rd quarter. AlphaCentric Advisors LLC now owns 13,299 shares of the biopharmaceutical company’s stock valued at $431,000 after buying an additional 515 shares during the last quarter. Handelsbanken Fonder AB grew its position in shares of Celldex Therapeutics by 5.0% in the 2nd quarter. Handelsbanken Fonder AB now owns 27,200 shares of the biopharmaceutical company’s stock valued at $1,012,000 after buying an additional 1,300 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Celldex Therapeutics in the third quarter valued at about $42,000. Finally, Nykredit A S bought a new stake in Celldex Therapeutics in the second quarter valued at approximately $67,000.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on the stock. Wells Fargo & Company lifted their target price on shares of Celldex Therapeutics from $48.00 to $72.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 29th. Canaccord Genuity Group upped their target price on Celldex Therapeutics from $60.00 to $68.00 and gave the company a “buy” rating in a research report on Monday. HC Wainwright reiterated a “buy” rating and set a $64.00 target price on shares of Celldex Therapeutics in a research report on Friday, October 2nd. Leerink Partners increased their price objective on shares of Celldex Therapeutics from $70.00 to $88.00 and gave the stock an “outperform” rating in a research report on Wednesday, September 23rd. Finally, Morgan Stanley upped their price target on Celldex Therapeutics from $57.00 to $61.00 and gave the stock an “overweight” rating in a research note on Monday. Eleven equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Celldex Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $64.08.

Celldex Therapeutics Stock Down 5.4%

Shares of NASDAQ:CLDX opened at $28.53 on Friday. Celldex Therapeutics, Inc. has a 12-month low of $22.33 and a 12-month high of $45.14. The business’s 50 day moving average is $32.19 and its 200 day moving average is $32.75.

Celldex Therapeutics (NASDAQ:CLDX) last posted its earnings results on Thursday, November 5th. The biopharmaceutical company reported ($0.96) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.02) by $0.06. The firm had revenue of $0.40 million during the quarter, compared to the consensus estimate of $0.72 million. Analysts forecast that Celldex Therapeutics, Inc. will post -4.12 EPS for the current fiscal year.

Celldex Therapeutics Profile

Celldex Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops antibody-based treatments for inflammatory diseases and cancer. Its research focuses on targets involved in immune responses and the activity of mast cells. The company’s lead candidate, barzolvolimab, is an antibody that targets the KIT receptor. Celldex is studying it for chronic urticaria and other conditions associated with mast-cell activity. Celldex also has early-stage oncology programs that investigate antibody therapies designed to affect immune pathways.